Cite
HARVARD Citation
Cappuzzo, F. et al. (n.d.). LBA53IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. Annals of oncology. p. . [Online].